Update in the treatment of intracranial atherosclerotic disease

Article Figures & Data

Table 1

Major Wingspan stent trials with mean time to treatment and complication rates

	Publication	Patients stented (n)	Percentage stented on label for stroke	Periprocedural complications %)	Time to stent from stroke or TIA (days)
HDE trial	Stroke, 200724	44	93	4.5	22
US registry	Stroke, 200727 Stroke, 201128	158	57	6.9	Not reported
NIH registry	Neurology, 200825	160	61	6.2	10
SAMMPRIS	New England Journal of Medicine, 20118	208	8.2	14.7	7
Jiang	Stroke, 201130	100	71	5.0	34
Miao	Stroke, 201529	141	56	4.3	19 for TIA/32 for stroke
Zhao	Journal of Stroke and Cerebrovascular Diseases, 201633	278	Not reported	4.3	21
Gao	American Journal of Neuroradiology, 201635	100	50	2.0	21
Ma	Stroke and Vascular Neurology, 201834	141	56	4.0	22
WEAVE	Stroke, 201937	152	100	2.6	22

HDE, Humanitarian Device Exemption; NIH, National Institutes of Health; SAMMPRIS, Stenting vs Aggressive Medical Therapy for Intracranial Artery Stenosis; TIA, transient ischaemic attack; WEAVE, Wingspan Stent System Post Market Surveillance.

Table 2

Comparisonsvn-2019 of 1-year stroke and death rates with medical therapy and stenting 21 days or longer after qualifying event

Medical therapy	Publication	Patients (n)	One-year stroke and death rate (%)
WASID	New England Journal of Medicine, 20057	569	18
SAMMPRIS	New England Journal of Medicine, 20118	227	12.2
COSS	The Journal of the American Medical Association, 20119	98	16
Total/mean event rate		894	15.4
Stenting
Jiang	Stroke, 201130	100	7.3
Li	PloS One, 201531	429	9.5
Wang	Neuroradiology, 201632	196	9.6
Zhao	Journal of Stroke and Cerebrovascular Diseases, 201633	278	5.8
Ma	Stroke and Vascular Neurology, 201834	141	7.9
Total/mean event rate		1134	8.0

COSS, Carotid Occlusion Surgery Study; SAMMPRIS, Stenting vs Aggressive Medical Therapy for Intracranial Artery Stenosis; WASID, Warfarin vs Aspirin for Symptomatic Intracranial Disease.

Vol 10 Issue 1 Table of Contents